来自官方财务报表的收入、利润与现金流历史。
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹38.1B | ₹37.3B | ₹34.4B | ₹32.3B | — |
| 毛利 | ₹23.9B | ₹22.5B | ₹20.2B | ₹18.7B | — |
| 营业利润（EBIT） | ₹12.5B | ₹11.1B | ₹8.4B | ₹7.5B | — |
| 净利 | ₹10.4B | ₹9.3B | ₹5.9B | ₹6.1B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 GLAXO 交互式查看器。 /companies/us/GLAXO
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms